AXSM: Axsome Therapeutics, Inc. Stock

by  •  • Comments Off on AXSM: Axsome Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 3,556.77
Enterprise Value ($M) 3,348.65
Book Value ($M) 190.98
Book Value / Share 4.02
Price / Book 18.62
NCAV ($M) 107.00
NCAV / Share 2.25
Price / NCAV 33.24

Profitability (mra)
Return on Invested Capital (ROIC) -0.63
Return on Assets (ROA) -0.61
Return on Equity (ROE) -2.14

Liquidity (mrq)
Quick Ratio 3.52
Current Ratio 3.63

Balance Sheet (mrq) ($M)
Current Assets 504.26
Assets 588.24
Liabilities 397.26
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 270.60
Operating Income -177.91
Net Income -239.24
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -145.08
Cash from Investing -0.58
Cash from Financing 331.01

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G/A Fairmount Funds Management LLC 4.90 0.64
02-14 13G/A Rtw Investments, Lp 9.50 50.63
02-13 13G/A Vanguard Group Inc 7.81 8.17
01-26 13G/A BlackRock Inc. 6.80 29.44

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-02-23 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2023-11-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT
2023-08-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S
2023-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-02 79,961 299,931 26.66
2024-05-01 96,166 412,532 23.31
2024-04-30 119,045 179,736 66.23
2024-04-29 85,438 170,823 50.02

(click for more detail)

Similar Companies
AVBP – ArriVent BioPharma, Inc. AVDL – Avadel Pharmaceuticals plc
AVTE – Aerovate Therapeutics, Inc. BCAB – BioAtla, Inc.
BIOR – Biora Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io

Finpedia: Axsome Therapeutics